HCM Hutchison China Meditech Ltd Sponsored ADR

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

Chi-Med to Attend Upcoming Industry and Investor Virtual Conferences

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“”) (Nasdaq/AIM: HCM) today announces that Mr. Christian Hogg, Chief Executive Officer of Chi-Med, will present or participate in the following virtual conferences:

  • The 15th Citi China Investor Conference on Thursday, November 5, 2020; and



  • The “China Summit Survey Results: Where is the "Bridge to Innovation" Headed?” Panel as part of the BioCentury-BayHelix 7th China Healthcare Summit on Monday, November 9, 2020.

Members of the management team will attend the above conferences in one-on-one meetings, and will also attend the following virtual investor conferences at certain times:

  • The Bank of America 2020 China Conference held from November 2 to 13, 2020;



  • The Goldman Sachs Asia Pacific Healthcare Forum held from November 16 to 18, 2020;



  • The 11th Annual Jefferies Global Healthcare Conference held from November 17 to 19, 2020;



  • The Morgan Stanley Asia Pacific Summit held from November 18 to 20, 2020; and



  • The Piper Sandler 32nd Annual Healthcare Conference held from December 1 to 3, 2020.

Further information are available at in the Shareholder Information section under “.”

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of nine cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: .

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med’s filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

Investor Enquiries 
Mark Lee, Senior Vice President+852 2121 8200
Annie Cheng, Vice President+1 (973) 567 3786
  
Media Enquiries 
Americas – Brad Miles, Solebury Trout+1 (917) 570 7340 (Mobile)

Europe – Ben Atwell / Alex Shaw, FTI Consulting+44 20 3727 1030 / +44 7771 913 902 (Mobile) /

+44 7779 545 055 (Mobile)

Asia – Joseph Chi Lo / Zhou Yi, Brunswick+852 9850 5033 (Mobile), /

+852 9783 6894 (Mobile),
  
Nominated Advisor 
Freddy Crossley / Atholl Tweedie,

Panmure Gordon (UK) Limited
+44 (20) 7886 2500

 

EN
30/10/2020

Underlying

Reports on Hutchison China Meditech Ltd Sponsored ADR

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Bi-Weekly: Poised For Strength

The HSHCI rose 1.8%, outperforming the HSI, which declined by 3.8% in the first two weeks of Feb 26. InSilico took the lead with a 16.9% share price increase, while CRO leaders WuXi AppTec and WuXi Bio gained 11.7% and 8.1% respectively. Innovent also outperformed its peers with a 9.2% rise. Fuelled by strong innovation, business development momentum, and robust 2025 results, the Chinese healthcare sector is expected to remain resilient in 2026. Maintain OVERWEIGHT.

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Internet Healthcare: Evolving Amid AI Innovation And Poli...

China’s internet healthcare segment is entering a new phase, fuelled by accelerating AI innovation from tech giants and policy support, eg the pilot programme for first-time online consultations. Despite profitability challenges, leading players are leveraging AI ecosystems and innovative strategies to position themselves for sustained long-term growth. We maintain BUY on Ali Health and PAGD. Maintain OVERWEIGHT on the China healthcare sector.

 PRESS RELEASE

HUTCHMED to Announce 2025 Final Results

HUTCHMED to Announce 2025 Final Results HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT). HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00...

Carol Dou Xiao Qin ... (+2)
  • Carol Dou Xiao Qin
  • Sunny Chen

Healthcare - Bi-Weekly: Stay Focused On Innovation

Since OpenAI’s launch of ChatGPT Health, internet healthcare share prices have fluctuated significantly. In the period 15-29 January, PAGD and Medlive dropped 15.5% and 21.7% respectively, while Ant Group-backed Ali Health remained relatively stable. Many drug innovators retreated 5-10% after an early rally, but AI-driven Insilico surged 18.8%. With robust innovative pipelines, rapid R&D, and growing product offerings, China's healthcare sector is poised to become a key player in the global mark...

Damon Shen ... (+2)
  • Damon Shen
  • Jieqi Liu

China Healthcare: Harnessing R&D Excellence For Global Expansion.

At the recent investor conference, global investors viewed Chinese healthcare companies with increasing interest and optimism. Impressed by their advanced R&D pipelines and swift R&D-to-market execution capabilities, investors recognised Chinese companies’ potential for innovation and growth, particularly as they presented an array of cuttingedge products ready for global markets. This positive perception reflects a growing confidence in China's healthcare sector as a key player on the internati...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch